Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
Authors:
Open Access
- 13 February 2013
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (6) , 1498-1505
Abstract
BRCA1 function is inactivated through BRCA1 promoter methylation in a substantial number of triple-negative breast cancers. We investigated the impact of BRCA1-methylation status on the efficacy of adjuvant chemotherapy in patients with triple-negative breast cancer or with non-triple-negative breast cancer. BRCA1 promoter methylation was assessed in 1163 unselected breast cancer patients. Methylation was evaluated using a methylation-specific PCR (MSP) assay. In the subgroup of 167 triple-negative breast cancer patients who received adjuvant chemotherapy, patients with BRCA1-methylated tumors had a superior 10-year disease-free survival (DFS)(78% versus 55%, P = 0.009) and 10-year disease-specific survival (DSS) (85% versus 69%, P = 0.024) than those with BRCA1-unmethylated tumors, and BRCA1 methylation was an independent favorable predictor of DFS and DSS in a multivariate analysis in this subgroup [DFS: hazard ratio (HR) = 0.45; 95% confidence interval (CI) 0.24–0.84; P = 0.019; DSS: HR = 0.43; 95% CI = 0.19–0.95; P = 0.044]. In contrast, in 675 non-triple-negative breast cancer patients who received adjuvant chemotherapy, BRCA1 methylation was an unfavorable predictor of DFS and DSS in univariate analysis (DFS: HR = 1.56; 95% CI 1.16–2.12; P = 0.003; DSS: HR = 1.53; 95% CI = 1.05–2.21; P = 0.026). Triple-negative breast cancer patients with BRCA1-methylated tumors are sensitive to adjuvant chemotherapy and have a favorable survival compared with patients with BRCA1-unmethylated triple-negative tumors.Keywords
Funding Information
- Program for Breast Cancer Tissue Bank of Beijing
- National Natural Science Foundation of China (30973436, 81071629)
This publication has 37 references indexed in Scilit:
- Triple-Negative Breast Cancer: An Unmet Medical NeedThe Oncologist, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Triple negative tumours: a critical reviewHistopathology, 2007
- Breast cancer risk associated with BRCA1 and BRCA2 in diverse populationsNature Reviews Cancer, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast CancerJournal of Clinical Oncology, 2006
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Cancer geneticsNature, 2001
- Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer casesBritish Journal of Cancer, 2000